Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

Habib Yaribeygi, Stephen Atkin, Amirhossein Sahebkar

Research output: Contribution to journalReview article

2 Citations (Scopus)


Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.

Original languageEnglish
Pages (from-to)1679-1683
Number of pages5
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Issue number2
Publication statusPublished - 1 Mar 2019



  • Diabetes mellitus
  • Hypertension
  • Oxidative stress
  • Sodium-glucose co-transporter inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this